Literature DB >> 28226414

Methylene Blue for the Treatment of Intractable Pain Associated with Oral Mucositis.

Carlos J Roldan1,2,3,4, Kent Nouri1, Thomas Chai1, Billy Huh1.   

Abstract

Oral mucositis is a common and often debilitating complication among cancer patients receiving radiation therapy to the head and neck or chemotherapy agents, or undergoing hematopoietic stem cell transplantation. Pain and decreased oral function associated with oral mucositis may persist long after the conclusion of therapy. Although most patients respond to conservative management, a subset of patients develops intractable pain with severe consequences. For some, the use of total parenteral nutrition with insertion of percutaneous endoscopic gastrostomy feeding tubes is the only alternative. Current recommendations to treat mucositis and its related pain include basic oral care, bland oral rinses, topical anesthetics, and systemic analgesics. We believe that chemical neurolysis of the affected areas with methylene blue used as an oral rinse is a noninvasive, efficient, safe, and cost-effective alternative that can provide prolonged analgesia in patients with intractable pain of oral mucositis. The benefits of this therapy are reflected in its improvement of patients' quality of life by enabling oral feeding and controlling pain. We report a series of 5 consecutive patients with intractable oral mucositis-related pain despite conventional treatment with systemic opiates. All 5 patients responded well to the use of 0.05% methylene blue as mouth rinse, demonstrating sustained analgesia over 3 weeks. The treatment was tolerated well, and overall patient satisfaction was very high. We also observed that methylene blue rinse significantly reduced the total opioid requirement, as demonstrated by reductions in the patients' morphine equivalent daily dose scores after its use. Our case series suggests that 0.5% methylene blue oral rinse therapy is an effective and inexpensive modality that can be used safely to palliate intractable oral pain in patients with mucositis associated with cancer treatment. To our knowledge, this is the first report using this therapy to treat pain from oral mucositis.
© 2017 World Institute of Pain.

Entities:  

Keywords:  adjuvants; cancer; intractable; pain

Mesh:

Substances:

Year:  2017        PMID: 28226414     DOI: 10.1111/papr.12566

Source DB:  PubMed          Journal:  Pain Pract        ISSN: 1530-7085            Impact factor:   3.183


  5 in total

1.  Methylene blue prevents osteoarthritis progression and relieves pain in rats via upregulation of Nrf2/PRDX1.

Authors:  Jia-Wei Li; Rong-Liang Wang; Jia Xu; Kuo-Yang Sun; Hui-Ming Jiang; Zi-Ying Sun; Zhong-Yang Lv; Xing-Quan Xu; Rui Wu; Hu Guo; Qing Jiang; Dong-Quan Shi
Journal:  Acta Pharmacol Sin       Date:  2021-04-08       Impact factor: 7.169

Review 2.  New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury.

Authors:  Marika Cinausero; Giuseppe Aprile; Paola Ermacora; Debora Basile; Maria G Vitale; Valentina Fanotto; Giuseppe Parisi; Lorenzo Calvetti; Stephen T Sonis
Journal:  Front Pharmacol       Date:  2017-06-08       Impact factor: 5.810

3.  Protein-protein interaction-based high throughput screening for adenylyl cyclase 1 inhibitors: Design, implementation, and discovery of a novel chemotype.

Authors:  Tiffany S Dwyer; Joseph B O'Brien; Christopher P Ptak; Justin E LaVigne; Daniel P Flaherty; Val J Watts; David L Roman
Journal:  Front Pharmacol       Date:  2022-09-06       Impact factor: 5.988

Review 4.  Methylene Blue Application to Lessen Pain: Its Analgesic Effect and Mechanism.

Authors:  Seung Won Lee; Hee Chul Han
Journal:  Front Neurosci       Date:  2021-05-17       Impact factor: 4.677

5.  Methylene blue relieves the development of osteoarthritis by upregulating lncRNA MEG3.

Authors:  Xinyi Li; Chaoliang Tang; Jin Wang; Peipei Guo; Chengyao Wang; Yanlin Wang; Zongze Zhang; Huisheng Wu
Journal:  Exp Ther Med       Date:  2018-03-02       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.